Characterization of the Growth Hormone Secretagogue Receptor in Dilated Cardiomyopathy by Naghibosadat, Maedeh
Western University 
Scholarship@Western 
Electronic Thesis and Dissertation Repository 
6-20-2019 2:00 PM 
Characterization of the Growth Hormone Secretagogue Receptor 
in Dilated Cardiomyopathy 
Maedeh Naghibosadat 
The University of Western Ontario 
Supervisor 
Dr. Savita Dhanvantari 
Imaging Program, Lawson Health Research Institute, London ON 
Dr. Lisa Hoffman 
Imaging Program, Lawson Health Research Institute, London ON 
Graduate Program in Pathology and Laboratory Medicine 
A thesis submitted in partial fulfillment of the requirements for the degree in Master of Science 
© Maedeh Naghibosadat 2019 
Follow this and additional works at: https://ir.lib.uwo.ca/etd 
Recommended Citation 
Naghibosadat, Maedeh, "Characterization of the Growth Hormone Secretagogue Receptor in Dilated 
Cardiomyopathy" (2019). Electronic Thesis and Dissertation Repository. 6321. 
https://ir.lib.uwo.ca/etd/6321 
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted 
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
i 
 
 
 
 
                                                  Abstract 
 
Duchenne muscular dystrophy (DMD) is a severe neuromuscular disease of skeletal and 
myocardial degeneration. Eventually, dilated cardiomyopathy develops from ischemia, 
inflammation and fibrosis. Due to the high mortality rate, there is an emerging need to 
diagnose DMD cardiomyopathy at early stages. Currently, DMD cardiomyopathy is 
diagnosed by imaging investigations and detection of circulating biomarkers. However, 
current imaging strategies detect functional and morphological changes but fall short in 
detecting molecular changes that underlie this disease. Circulating biomarkers provide 
information on the molecular level, but they are not cardiac-specific. Therefore, there is an 
emerging need for a biomarker that is endogenous to cardiac tissues. The growth hormone 
secretagogue receptor (GHSR) and its ligand, ghrelin are produced by both cardiomyocytes 
and vascular endothelial cells and could be an indicator of DMD cardiomyopathy. The 
work described in this thesis sought to characterize GHSR as a cardiac-localized biomarker 
in DMD cardiomyopathy. Histopathology and confocal imaging using a novel fluorescent 
ghrelin analog, Cy5-ghrelin (1-19), were used to investigate changes in cardiac tissue 
architecture and GHSR and inflammatory markers in the mdx:utrn-/- mouse model of DMD.  
My studies show that GHSR is elevated in mdx:utrn-/- myocardial tissues and correlate 
strongly with the macrophage marker F4-80 and the pro-inflammatory cytokine IL-6. 
Interestingly, I also show that both ghrelin and des-acyl ghrelin bind to sites in large cardiac 
vessels of mdx:utrn-/- which might be an indicator of vascular inflammation. Finally, my 
project shows the first report of GHSR in cardiac macrophages. In summary, my work 
suggests that, in dilated cardiomyopathy, elevations in GHSR correlate with the 
inflammatory phenotype as mediated by both the myocardium and macrophages. 
Keywords:  
Dilated cardiomyopathy, Duchenne Muscular Dystrophy, GHSR, Inflammation, 
Biomarker, mdx:utrn-/ 
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Lay Summary 
 
 
Heart disease is the leading cause of death in Canada. It is usually diagnosed by imaging, 
such as ultrasound. However, this kind of imaging can miss small changes in the heart that 
lead to heart disease. My work has addressed this issue by identifying a protein located in 
the heart muscle that may indicate the onset of heart disease. I showed that this protein, 
called GHSR, is increased in the heart in a mouse model of heart disease, along with the 
degree of inflammation in the heart. My research has shown that there may be more 
sensitive ways of detecting heart disease, so that it may be diagnosed at earlier stages. 
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                                                    Chapter 1 
 
1 Introduction 
 
1.1 Significance of the study 
 
The heart is a muscular organ that pumps blood through the blood vessels of the body. In 
doing so, oxygen and nutrients are delivered, and metabolites are excreted. When the cells 
that make up the muscular portion of the heart, the cardiomyocytes, become dysfunctional, 
the heart becomes inefficient in its ability to pump blood, and the result is cardiomyopathy. 
There is a critical need to detect cardiomyopathy in its earlier stages, prior to the onset of 
overt symptoms.  To address this need, our lab is developing new ways for the molecular 
imaging of the heart both in situ and in vivo. We have identified a possible biomarker of 
heart disease, the growth hormone secretagogue receptor (GHSR) and its ligand, ghrelin. 
Our lab has developed ghrelin analogs as molecular imaging tools that enable the imaging 
of GHSR in vivo through PET imaging and in situ through fluorescence microscopy of 
tissues. The work described in this thesis uses fluorescence molecular imaging to show that 
GHSR is elevated in a type of highly inflammatory and fibrotic dilated cardiomyopathy in 
a mouse model of muscular dystrophy, implicating the ghrelin/GHSR system as a 
biomarker in cardiomyopathy. 
 
 
1.2 Cardiovascular disease 
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Cardiovascular disease (CVD) remains one of the greatest burdens of human disease and 
mortality globally1. In Canada, CVD is responsible for 19.7% of total annual death. 
Therefore, CVD places a heavy burden on the Canadian health care system which is 
estimated at $29 billion per year.2 3 
A wide array of conditions is classified as cardiovascular disease: peripheral blood vessel 
diseases, coronary artery diseases, arrhythmia, inflammatory heart disease and 
cardiomyopathy. To diagnose and treat each of these complex conditions, innovative 
approaches are required .4 5 Although coronary artery disease is the largest contributor to 
cardiovascular diseases, cardiomyopathies are clinically very devastating.6 For example, 
50%  of cardiomyopathy patients die suddenly in their childhood or adolescence.7  
 
1.3 Cardiomyopathies 
Cardiomyopathies are structural myocardium abnormalities associated with cardiac 
dysfunction.  Cardiomyopathies are categorized based on their  morphology and function 
into hypertrophic, restrictive, dilative and arrhythmogenic right ventricular subtypes which 
might overlap genetically and phenotypically. 2 8  
Hypertrophic cardiomyopathy is a disorder in which the ventricular wall thickness or mass 
is increased in the absence of a loading condition such as hypertension or valve disease. 
Myocyte hypertrophy occurs  due to interstitial infiltration or intracellular accumulation of 
metabolic substrates.9 10 11 
Restrictive cardiomyopathy refers to a pattern of ventricular filling that results in 
myocardium stiffness and causes a precipitous rise in ventricular pressure. RCM is difficult 
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to define since it occurs in numerous pathologies.  But based on more specific 
classification, RCM is characterized by restrictive ventricular physiology in the presence 
of reduced systolic and diastolic volume with normal ventricular wall thickness. 12 13 14 
Arrhythmogenic right ventricular cardiomyopathy is defined by progressive substitution of 
right ventricular myocardium by adipose and fibrotic tissue with associated arrhythmia. 
These pathologic and histologic abnormalities are a result of disruptions to the inflow and 
outflow of blood through the right ventricle. 8 15 16 17 
Dilated cardiomyopathy (DCM) is the most common subtype of cardiomyopathy due to its 
involvement with other diseases and it is the focus of this thesis. 
1.4 Dilated Cardiomyopathies 
 DCM is a serious clinical concern due to its high prevalence and the high likelihood of 
heart failure (HF) in the later stages of the patient’s life. The prevalence of DCM is 
estimated to be at least 1:2500; it is the third most common cause of heart failure and the 
most frequent cause of heart transplantation.2 18 However, DCM is underdiagnosed as some 
patients remain asymptomatic until marked ventricular dysfunction takes place; therefore, 
the prevalence may be as high as 1:250.19 20 
DCM is characterized by dilation of the left ventricle and systolic dysfunction.  The 
ventricular myocardium, mainly the left ventricle, undergoes a combination of thinning 
and stretching which results in chamber enlargement and impaired contractility. This 
structural change leaves the patients at higher risk of HF which could spread to the other 
heart chambers. The DCM patients suffer from symptoms such as swelling of the lower 
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extremities, fatigue, shortness of breath, arrhythmia and valve problems.21 The typical age 
of occurrence is between 20 to 60 years, and it is more prevalent in men than women. 22 23   
DCM could be genetic and non-genetic. The non-genetic DCM may occur as a result of  
bacterial and viral infections or autoimmunity. 19 24 In genetic DCM, the mode of 
inheritance is typically autosomal and X-linked. The autosomal forms of DCM are caused 
by mutations in the genes that encode cytoskeletal (actin, myosin, tropomyosin, troponin 
I, troponin C, troponin T and vinculin), sarcomeric (sarcoglycan) and nuclear (lamin) and 
Z-band (titin) proteins. DCM also occurs in mitochondrial cytopathies.17 19 24  Additionally, 
neuromuscular disorders such as Duchenne muscular dystrophy (DMD) and Becker 
muscular dystrophy (BMD) are  X-linked muscular disorders which exhibit the DCM 
phenotype. 21 25  The focus of this thesis is DMD dilated cardiomyopathy. 
 
1.5 DMD Dilated Cardiomyopathy 
1.5.1 Duchenne Muscular Dystrophy 
 
Duchenne muscular dystrophy (DMD) affects approximately 30,000 boys in North 
America, making it the most fatal disorder in early childhood.26 It is an X-linked 
neuromuscular disease caused by mutations in the gene encoding dystrophin.   
Dystrophin is one of the largest human proteins with a molecular weight of 427 kDa and 
is located within myocytes on the cytosolic side of the sarcolemma. Dystrophin acts as a 
bridge to connect the cytoskeletal F-actin to laminin in the extracellular matrix and is an 
important component of the dystrophin-associated protein complex or DAPC, that is also 
composed of dystroglycans, dystrobrevins, sarcoglycans, and syntrophins (Figure 1). This 
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vital complex is a crucial link between the extracellular matrix (ECM) and the intracellular 
actin cytoskeleton and serves two functions: to maintain the structural integrity of the 
muscle fiber and to act as a scaffold for signaling proteins. Through interactions with 
dystrophin, several structural proteins provide stability, deformability and muscle integrity 
during skeletal muscle and cardiac contraction.27 28 A major signaling protein is neuronal 
nitric oxide synthase (nNOS), which is localized to the sarcolemma by dystrophin and 
catalyzes the synthesis of nitric oxide (NO), which facilitates vasorelaxation. 
 
Figure 1: Dystrophin links the ECM to cytoskeletal and signaling proteins. 
This schematic illustrates the key location of dystrophin (green) at the sarcolemma 
of a myocyte, where it mediates interactions between the DAPC, the actin 
cytoskeleton and the intracellular signaling protein nNOS. 29 30 
 
 
1.5.2 DMD Cardiac Pathology 
The absence of dystrophin in skeletal muscle is the cause of Duchenne muscular dystrophy 
(DMD). One complication of DMD is dilated cardiomyopathy, characterized by a 
combination of ischemia, inflammation and fibrosis that is caused by an absence of 
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dystrophin in cardiomyocytes. These cardiac cells comprise the involuntary striated muscle 
(myocardium). Compared to skeletal myocytes, cardiomyocytes are short and branched 
and connected to their neighbors via intercalated disks, forming a strong, contractile muscle 
network.  
Located within the sarcolemma of cardiomyocytes are L-type calcium channels which 
promote the influx of calcium ions from the extracellular matrix into the cells and 
contribute to the depolarization of the cardiomyocytes to maintain and generate contractile 
action.31 The absence of dystrophin leads to the loss of integrity of the sarcolemma and 
shearing during myofiber contraction.32 33 The damaged membrane allows for abnormal 
calcium ion influx that activates calpain proteases, which can auto-digest the 
cardiomyocytes. Calpain proteases also degrade cardiac troponin I, part of the troponin-
actin-tropomyosin complex that mediates  contractility.27 34 
The abnormal calcium flow in cardiomyocytes also increases the level of reactive oxygen 
species, which stimulates the NF-B signaling pathway, triggering the release of pro-
inflammatory cytokines and resulting in immune response at the site. Subsequently, 
macrophages are recruited to the tissue for cell debris removal. Macrophages also attack 
the cardiac myofibers, thus exacerbating the sarcolemmal damage and leading to 
myonecrosis. Macrophages are the most abundant immune cells in DMD cardiac muscle 
and both M1 (pro-inflammatory) and M2 (regenerative) phenotypes are present at the site 
of cardiac injury. T-cells, B-cells and dendritic cells also found at the site, with CD4+ T-
cells being predominant to CD8+ T-cells in DMD heart. Furthermore, in the process of 
myonecrosis, inflammatory macrophages release pro-inflammatory cytokines, which 
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triggers the fibroblasts in the extracellular matrix to produce collagen, leading to fibrosis.35 
36 37  
The pro-inflammatory cytokines TNF-α and IL-6 are elevated in the plasma of DMD 
patients.38 TNF-α is associated with T-helper cells type-1 (Th1) and is upregulated 1000 
times in DMD patients compared to healthy people. Studies have shown higher mRNA 
expression of TNF-α in the lymphocytes of DMD patients.39 As well, in a mouse model of 
DMD, the diaphragm contains a significant amount of TNF-α mRNA, and TNF-α 
colocalizes strongly with macrophage infiltrates.40  
IL-6 is another pro-inflammatory cytokine that is elevated in DMD patients. It is associated 
with T- helper cells type 2 (Th2). IL-6 exerts its pro-inflammatory effects via activation of 
the NF-B pathway.40 The concentration IL-6 is 4 times higher in the serum of DMD 
patients compared to the aged-matched controls. The levels of IL-6 mRNA in DMD 
skeletal muscles is significantly higher than in healthy muscles.41 However, whether IL-6 
or TNF-α is elevated in the DMD heart is not known. 
Dystrophin also plays a role in maintaining adequate blood flow in the muscle through 
regulation of nNOS. Without dystrophin, nNOS does not attach properly to the 
sarcolemma; instead, it is mislocalized to the cytosol, where it activates metabolites that 
function in vasoconstriction, leading to inadequate blood flow and muscle ischemia. In 
addition, dystrophin deficiency in vascular smooth muscle cells also negatively impacts 
vasoregulation.42 43 
As a result of progressive loss of contractile function, increasing fibrosis and ischemia, the 
cardiac muscle regenerative capacity decreases with age, and the cardiac myofibers are 
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gradually replaced by connective and adipose tissues, 44 45 eventually resulting in 
conduction defects and dilated cardiomyopathy after 10 years of age.46  The progression of 
this cardiac defects worsen over time and will be present in all patients by 18 years of age 
and leading progressively to heart failure and is present in about 90% of patients. Initially, 
DMD patients have a normal heart but eventually, the inferobasal wall becomes fibrotic 
leading to hyper-trabeculation and dysfunction of the left ventricle which results in 
decreased contractility. Unfortunately, the cardiac complication of DMD is largely 
asymptomatic until heart function is severely hindered. 26 27 33 47 
1.5.3 Pre-clinical models of DMD  
Animal models play a vital role in pre-clinical diagnostic and therapeutic research and 
provide insights into disease mechanisms. To study DMD, there are numerous mammalian 
models, including canine, feline and mouse models. The canine X-linked muscular 
dystrophy model demonstrates a rapid progressive muscular phenotype along with a slow 
progression to the left ventricular dilation and decreased systolic function. However, the 
canine model shows a variable disease severity and cardiac involvement and fibrosis that  
only occur after several years. 48 25 49 50 The hypertrophic feline muscular dystrophy model 
exhibits prominent hypertrophic muscle phenotype but very slight cardiac involvement. 
Therefore, the feline model is not translatable to the human cardiac condition. Additionally, 
both models are relatively large and require sophisticated and costly housing which is 
problematic for research use. 25 49 51 
          1.5.3.1   Mouse models of DMD 
Rodent models, specifically mice, have become popular in research due to the wide range 
of inbred and genetically modified strains that resemble DMD in humans. There are 
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numerous single-knockout and double-knockout DMD strains, such as knockouts of 
dystrophin alone (mdx), or in combination with utrophin (mdx:utrn-/-), α7-integrin 
(mdx:itga7-/-), MyoD (mdx:myod-/-), desmin (mdx:des-/-), dystrobrevin (mdx:adbn-/-),and 
parvalbumin (mdx:pv-/-).25 52 53 
By far, mdx mouse is the most widely DMD model. Similar to DMD patients, the mdx 
mouse has a nonsense mutation in the X-chromosome dystrophin gene which results in 
halting the synthesis of the dystrophin protein. Hence, the mdx mice are greatly applicable 
in skeletal muscle research. However, strain’s applicability for DMD cardiomyopathy 
research is limited, since the mdx model exhibits mild and non-progressive cardiomyopathy 
only after 10 months of age. The mild phenotype of mdx mice may be due to the 
upregulation of the protein utrophin, which is the dystrophin homolog. Utrophin 
structurally substitutes and partially compensates for dystrophin in the DAPC in mice, but 
not in humans.53 54 55 
In contrast, the mdx:utrn-/- mouse model, which is deficient in both dystrophin and utrophin 
production, demonstrates severe skeletal muscle degeneration along with cardiac 
dysfunction which phenocopies the human condition. These mice also exhibit abnormal 
gait, hind limb weakness, kyphosis, abnormal ECG and respiratory failure. They generally 
fail to survive after 20 weeks of age. The development of cardiomyopathy in these mice 
has been mapped using different imaging modalities such as 3D ultrasound and computed 
tomography (CT) perfusion. 25 56 57 58 59 
 
1.6   Imaging Modalities for detecting DCM 
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 Diagnosis of cardiomyopathy in DMD is difficult since the patients have reduced exercise 
tolerance that masks the cardiac problem. DMD patients suffer from immobility, 
pulmonary failure, and scoliosis, which obscures the clinical and radiographic symptoms 
of heart failure. 37 60 Clinically, cardiac involvement is mainly diagnosed at later stages 
through electrocardiography and echocardiography and sometimes detected by cardiac 
magnetic resonance imaging (MRI), computed tomography (CT) and radionuclide 
imaging.61 62 63 64 
 
1.6.1 Electrocardiography and Echocardiography 
Electrocardiography (ECG) and echocardiography are common clinical imaging tools used 
to identify the structural and functional cardiac changes. ECG analyzes the electrical 
activity within the heart while echocardiography assesses cardiac function by ultrasound 
imaging. It is frequently used to elucidate changes in heart shape and size, along with the 
excess fluid characteristics (pulmonary congestion, pleural effusion). ECG detects left 
ventricular hypertrophy and cardiac arrhythmias that indicate the onset of 
cardiomyopathies that can lead to heart failure.26 65 
Echocardiography is also a powerful diagnostic tool that gives information about the 
ventricular size and valvular abnormalities. It enables clinicians to diagnose 
cardiomyopathy by measuring cardiac systolic function by ejection fraction (EF) which 
represents the fraction of blood pumped out of the ventricle with each heartbeat. 37 62 66 67 
Both techniques are relatively cost-effective and widely used in clinics. However, they 
provide information on structural changes that occur in the later stages of heart disease, 
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when the patient is experiencing outward symptoms. Additionally, echocardiography 
requires professional acquisition and images might be variable based on the observant 
expertise.65 61 68 
 
1.6.2  Cardiac MRI and CT  
Cardiac MRI detects early structural changes in DCM. It reveals three-dimensional 
information regarding heart size, the thickness of the ventricular wall, and function 
information such as ejection fraction, blood flow, fibrosis, edema, hemorrhage and changes 
in soft tissue.  MRI is an invaluable tool which is used to diagnose and evaluate cardiac 
muscle abnormalities at an early stage in a non-invasive manner without exposure to 
radioactivity. In the clinic, gadolinium contrast-enhanced MRI aids in identifying areas of 
myocardial fibrosis. However, it cannot detect the diffuse fibrosis which is notable in DMD 
cardiomyopathy. Also, MRI for DMD patients may be limited, as many patients bear 
assistive implanted devices as mobility aids, which are not compatible with MRI.69 70 71 
CT is another imaging modality which yields three-dimensional high resolution anatomic 
and morphologic information. Image contrast is dependent on the degree of x-ray 
attenuation by different tissues and can be enhanced by the injection of barium or iodine-
based contrast agents. Contrast-enhanced CT has extremely high resolution and is excellent 
for imaging blood vessels, especially coronary arteries. Contrast agents are also used for 
coronary angiography to visualize arterial stenosis. Another type of CT, CT perfusion, 
measures myocardial blood flow and blood volume. The main concern to use the contrast-
enhanced CT is the risk of radiation exposing the children with DMD. As the acceptable 
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radiation dosage for the DMD children has not been determined. The contrast agent may 
also cause an allergic reaction. 72 73 74 
To date, all standard diagnostic imaging tools for the detection of DMD cardiomyopathy 
yields information on structural changes in the heart. What is missing are indicators of the 
progression of heart disease at a molecular level, which can potentially detect the onset of 
cardiomyopathy at earlier or subclinical stages. 25 Therefore, from a clinical point of view, 
there is a critical need for tissue biomarkers that can identify the different stages of 
cardiomyopathy and predict the response to the therapy.  
 
 
1.7 Biomarkers for DCM 
Biomarkers are measurable indicators of biological conditions and may potentially identify 
the molecular mechanisms at different stages of cardiomyopathy progression. Ideally, a 
cardiac biomarker should comprise qualities such as: 1. Provide accurate and repeatable 
measurements; 2. Be present at early stages of cardiomyopathy pathogenesis; 3. Be highly 
sensitive to sub-clinical cardiac changes; 4. Be Cardiac-localized and 5. Be Metabolically 
stable and not be degraded. 69 71 75 Currently, natriuretic peptides and cardiac troponins are 
clinically used as biomarkers for DMD cardiomyopathy.60 76 Specifically, elevated levels 
of circulating brain natriuretic peptide (also known as B-type natriuretic peptide, BNP), N-
terminal pro-BNP (NT-pro-BNP) and cardiac troponins I & T indicate cardiomyocyte 
stress and injury and are used as a diagnostic tool for HF and DCM patients.  
The hormone BNP, along with NT-pro-BNP, is secreted by ventricular cardiomyocytes 
upon increased wall stretching, and pressure overload as occurs in DCM. Both BNP and 
NT-proBNP are produced by the post-translational processing of proBNP, and N-terminal 
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pro-BNP is more stable than BNP in plasma.  Plasma BNP levels of more than 100 pg/mL  
and NT-pro-BNP levels of more than 900 pg/mL are indicators of heart dysfunction. 77 78  
While BNP is commonly used as a diagnostic tool in the clinic, there are several limitations 
to its use as a biomarker for cardiomyopathy. First, BNP is a biomarker for severely 
depressed Left Ventricular Ejection Fraction (LVEF) but not for early-stage dysfunction in 
the left ventricle. Therefore, it cannot determine early stages of the cardiomyopathy.78 79 
Second, there are other non-cardiac factors that affect circulating levels of BNP such as 
obesity and renal failure .80 81 Both BNP and NT-pro-BNP are also elevated in the plasma 
with age. These results suggest that elevated BNP levels may not be specifically due to 
cardiomyopathy and may vary depending on disease severity and genetic polymorphism.   
 The other biomarker is troponin that is a regulatory protein and present in the myofibers 
of striated muscles. It comprises three subunits that are products of different genes: C, I 
and T. Troponin C is not specific to cardiac muscle and it is not used in the clinic since its 
isoform is shared by skeletal muscle. Cardiac troponin I and cardiac troponin T are 
biomarkers of cardiac stress and historically used to diagnose myocardial infarction.  While 
increases in circulating levels of both cardiac troponins I and  T are associated with 
myocardial necrosis and remodeling, the assay for troponin I assay is the most sensitive 
and specific test in the clinic.82 In DMD, increased cardiomyocyte sarcolemma 
permeability and stretching leads to the release of troponins from the cytosolic pool. 
Furthermore, an increase in cardiac ventricular wall stress causes cardiomyocyte apoptosis 
and disruption of the contractile force resulting in troponin release. However, cardiac 
troponins are also elevated in other cardiovascular diseases such as hypertrophic 
14 
 
 
 
cardiomyopathy, hypertension, myocarditis and cardiac amyloidosis and only provide 
information at the late stages of DMD cardiomyopathy. 75 83 84  
Although both circulating biomarkers are detectable by a simple blood test, they are not 
specific to the heart and may be produced by other tissues in response to injury. Moreover, 
circulating levels might not be representative of those found within the cardiac tissue. 
Therefore, it is necessary to identify cardiac- localized biomarkers for DMD 
cardiomyopathy. 68 
One possible biomarker is the cardiac-localized is the growth hormone secretagogue 
receptor (GHSR) and its ligand, ghrelin. I will now elaborate on the ghrelin/GHSR system 
as a cardiomyopathy biomarker. 
 
1.7.1 GHSR and ghrelin: general physiology 
Ghrelin and its receptor, GHSR, represent a potential candidate biomarker for 
cardiomyopathy. Ghrelin is a 28 amino-acid peptide hormone and is the natural ligand of 
GHSR, a seven-transmembrane, G protein-coupled receptor.  This peptide hormone plays 
an important role in systemic metabolism by appetite stimulation and food intake 
regulation. Ghrelin levels in plasma are raised in the fasted state and reduced after a meal.85 
Mature bioactive ghrelin is produced from the post-translational cleavage of pro-ghrelin 
(117 amino-acid) and is octanoylated on serine 3 by ghrelin O-Acyltransferase (GOAT), 
which enables binding to GHSR. The proportion of ghrelin that does not bear this 
modification is termed des-acyl ghrelin and does not bind to GHSR.86 
15 
 
 
 
Molecular features of ghrelin are located in N-terminal region, particularly in residues 1-8 
of the peptide which is required for activation of GHSR.87 The binding of ghrelin to GHSR 
induces signaling through Gαq11 which results in growth hormone release.88 
Ghrelin was originally isolated from rat and human stomachs, but it is also synthesized in 
and secreted from other tissues including those of the cardiovascular system.85 89 Specific 
binding of ghrelin in cardiovascular tissues such as myocardium, aorta, coronary arteries, 
pulmonary arteries and veins has been reported, demonstrating that  GHSR is expressed 
throughout the cardiovascular system.90  
 
1.7.1.1 Ghrelin & GHSR in the Cardiovascular System 
The expression of myocardial GHSR and the production of ghrelin from cardiomyocytes 
and vascular endothelial cells suggests the presence of ghrelin/GHSR system in the heart 
that operates independently of its function in the regulation of appetite.89  One study has 
shown that ghrelin had effects on the cardiovascular system through GHSR in GH-deficient 
rats, further demonstrating the independence of the cardiovascular ghrelin/GHSR system91 
92 As well, ghrelin synthesis by the myocardium and cultured cardiomyocytes suggests that 
ghrelin could have autocrine and paracrine effects in cardiac muscle.93 94 
The binding of GHSR by ghrelin activates numerous signaling pathways that mediate the 
cardiovascular effects of ghrelin.95 At the level of the cardiomyocyte, these effects include 
the promotion of contractile activity, stimulation of angiogenesis and proliferation, and 
inhibition of apoptosis.91 
Activation of GHSR by ghrelin results in subsequent activation of phospholipase C (PLC), 
which cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into IP3 and diacylglycerol. 
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Diacylglycerol binds to and activates PKC, which then activates L-type voltage-dependent 
Ca2+ channels in the sarcolemma, and IP3 facilitates calcium release from the sarcoplasmic 
reticulum (SR), which is necessary for cardiomyocyte contraction.95 The binding of ghrelin 
to myocardial GHSR also activates other molecular pathways such as PI3K and AKT that 
promote angiogenesis, cell proliferation and migration.96 Signaling through PI3K and 
ERK1/2 is also associated with inhibiting apoptosis. Ghrelin inhibits apoptosis induced by 
doxorubicin in cardiomyocytes by elevation of the antiapoptotic factors IGF-1 and 
cardiotrophin-1 (CT-1). Therefore, ghrelin activation of GHSR in cardiomyocytes 
promotes contractile activity and survival and inhibits apoptosis.97 
Several studies conducted in various animal models of heart disease provide evidence for 
the cardioprotective effects of the ghrelin/GHSR system and its potential for diagnosis and 
treatment of cardiovascular diseases. Administration of ghrelin in an ischemia-reperfusion 
rat model decreased infarct size and improved left ventricular function. 91 98 Ghrelin also 
attenuated left ventricular remodeling in rats after myocardial infarction as well as in obese 
mice.99 100 In animal models of HF, ghrelin administration improved myocardial 
contractility and reduced cachexia.101 
In humans, ghrelin administration also improved cardiac output in patients with congestive 
HF, suggesting that ghrelin may have a therapeutic role in HF.89 In healthy humans, 
intravenous ghrelin injection improved cardiac output and contractility and reduced arterial 
pressure with no changes in heart rate.102 Nagaya et al. reported that ghrelin administration 
improved left ventricular function by attenuating left ventricular remodeling in chronic HF 
patients. They also showed that ghrelin administration reduced the vascular resistance and 
improved the stroke index and cardiac output in chronic HF patients.103 They also observed 
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that ghrelin treatment boosted the lean body mass, muscle strength, and oxygen 
consumption during exercise, suggesting that ghrelin may reduce the extent of muscle 
wasting in chronic HF patients.103  
Ghrelin action in the vasculature and particularly endothelial cells is complex due to the 
activation of different pathways. Ghrelin binding to GHSR on endothelial cells promotes 
NO synthesis through activation of PI3K/AKT and eNOS signaling pathways.104 Tesauro 
et al. showed that ghrelin could reverse endothelial cell dysfunction in metabolic syndrome 
patients through an increase in NO bioavailability, thereby suggesting a role for ghrelin in 
vascular hemostasis 105. Signaling through the PI3K/AKT pathway also leads to protection 
of endothelial cells against oxidative stress and apoptosis.95 106 
 
 
 
                                     
1.7.1.2 Ghrelin & GHSR in Inflammation 
 
Ghrelin may have an anti-inflammatory role in the immune and vascular system. Studies 
have demonstrated that levels of GHSR are increased in acute vascular inflammation. 
Human coronary endothelial cells and smooth muscle cells incubated with 
lipopolysaccharide to induce inflammation showed increased GHSR mRNA levels, and 
inflammation was attenuated after treatment of the cells with ghrelin. 107 Ghrelin also 
hindered the production of the pro-inflammatory cytokine IL-8 and NF-B signaling 
activation in human umbilical vein endothelial cells (HUVECs)  treated with TNF-α.108  
Ghrelin also has direct anti-inflammatory effects on immune cells. It has been shown that  
GHSR is expressed in human monocytes and T-cells, and treatment with ghrelin blocks the 
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secretion of the pro-inflammatory cytokines IL-1, IL-6 and TNF-α. 109 In vivo, treatment 
of a rat model of arthritis with a ghrelin analog for eight days attenuated the level of 
inflammation by reducing the plasma concentration of cytokines.110  
 The anti-inflammatory effect of ghrelin has also been reported in acute myocardial 
inflammation. Ghrelin injection ameliorated the inflammatory post-infarction myocardial 
remodeling in rats induced by coronary artery ligation. Subcutaneous injection of ghrelin 
decreased the left ventricular remodeling and scar thickness and inhibited the inflammatory 
response  as determined by reductions in mRNA and protein levels of IL-1 and TNF-α. 111 
Since ghrelin appears to have cardioprotective and anti-inflammatory effects on 
cardiomyocytes and vascular endothelial cells through GHSR, we need to have more 
insight into patterns of GHSR changes in cardiomyopathy. Since DMD dilated 
cardiomyopathy is a combination of inflammation, ischemia and fibrosis, elucidating the 
relationship between inflammation and GHSR in this condition could provide more 
insights into the progression of dilated cardiomyopathy.  
 
1.7.1.3 Our GHSR strategy 
Our collaborative research group has developed and characterized novel fluorescent tools 
for the detection of GHSR in situ. In particular, we have generated peptide analogs of 
ghrelin and des-acyl ghrelin conjugated to the far-red fluorophore, Cy5: Cy5-ghrelin (1-
19) and Cy5-des-acyl ghrelin (1-19). Using these tools, our previous work demonstrated 
that only the octanoylated form of ghrelin bound to GHSR in murine cardiomyocytes112. 
With the Cy5-ghrelin(1-19) probe we were also able to track the differentiation of P19 cells 
into cardiomyocytes, demonstrating that we can follow changes in GHSR over time.112 
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Using Cy5-ghrelin (1-19), our lab showed that levels of cardiac GHSR decreased in a 
mouse model of diabetic cardiomyopathy which represented early-stage DCM113, and 
investigated the dynamics of GHSR before and after cardiac transplantation in humans with 
end-stage HF. In this important study, we also found an inverse correlation between LVEF 
and myocardial GHSR levels and demonstrated that GHSR may be more sensitive than 
BNP as a cardiac-localized biomarker for HF. 114 
Overall, our lab has identified the GHSR/ghrelin system as a possible cardiac-localized 
biomarker for human end-stage HF and the early stages of murine diabetic 
cardiomyopathy. These findings led to my study investigating if GHSR is a biomarker in 
the highly inflammatory and fibrotic cardiomyopathy of DMD.  
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1.8 Central Hypothesis 
My studies focused on characterizing changes in GHSR, ghrelin and inflammatory markers 
in the heart and cardiac microvasculature, in a mouse model of DMD cardiomyopathy.  
Hypothesis:  I hypothesize that GHSR levels positively correlate with the severity of 
cardiac and vascular inflammation in DMD  
The aims of this project are: 
1. To characterize GHSR and inflammatory markers in late-stage cardiomyopathy 
in a mouse model of DMD 
2. To characterize GHSR in mouse vascular endothelial cells and its correlation with 
levels of induced inflammation 
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Chapter 2 
 
2   Material and Methods 
 
2.1 Animal models 
Experiments were performed at The Lawson Health Research Institute at St. Joseph’s 
hospital in London, Ontario. All animal protocols were approved (Ethics approval #2008-
067) by the Western University Institutional Animal Use Subcommittee and conducted 
according to guidelines set by the Canadian Council on Animal Care (CCAC).  
2.1.1 Wild type (C57BL/6 Mice) 
 As a negative control, wild-type C57BL/6 mice were purchased from Charles River 
Laboratories (Wilmington, MA, USA) at the age of 4-5 weeks and housed at the Lawson 
Health Research Institute Animal Care Facility. Mice were maintained in controlled 
conditions (19-23˚C, 12-hour light/dark cycles), fed regular mouse chow and monitored 
daily to ensure their health. Food and water were provided ad libitum. 
 
   2.1.2 Heterozygous mdx mice (mdx:utrn+/-) 
Heterozygous mdx mice (mdx:utrn+/-) were generously provided by Dr. Robert Grange, 
Virginia Polytechnic Institute and State University, Blacksburg, VA, USA. This strain 
was originally generated by Dr. Mark Grady and Dr. Joshua Sanes from Washington 
University, St. Louis, MO, USA. Heterozygous utrophin mdx mice (mdx:utrn+/-) have an 
intermediate disease phenotype compared to the double knockout mice.115  
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 2.1.3 Mouse model of DMD mice (mdx:utrn-/-) 
 Heterozygous mdx mice were crossed to generate mdx:utrn-/-mice which lack both 
utrophin and dystrophin. Only male groups of wild-type and mdx:utrn-/- mice at the age of 
15-17 weeks were used in this study. At this age range, mdx:utrn-/-  mice demonstrate the 
severe phenotype of DMD disease 53 and do not tend to live past 20 weeks of age. In this 
thesis, the DMD mouse refers exclusively to the mdx:utrn-/- mouse. 
 
2.2 Animal genotype validation 
For genotyping, tail snips or ear-notches were collected, and DNA was extracted according 
to the standard PCR genotyping protocol. Briefly, tail snips or ear-notches were lysed using 
Proteinase K at 55° C overnight. Then, the polymerase chain reaction (PCR) was performed 
by Taq polymerase enzyme (Biolabs, M0267E) to amplify the utrophin gene.52  
The set of primers that were used to confirm the presence of utrophin were: 
5’- TGCCAAGTTCTAATTCCATCAGAAGCTG -3’ (forward primers)   
and 5’- CTGAGTCAAACAGCTTGGAAGCCTCC-3’ (reverse primer) 
Gene deletion was confirmed by the existence of a band at 310 kb on a 1% agarose gel 
containing ethidium bromide. 
 
 
2.3 Heart sample preparation 
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All hearts were obtained from mice from a previous study in which cardiomyopathy had 
been measured by determining left ventricular ejection fraction through micro-CT and 3D 
echocardiography.59 In that study, the hearts from each of three 15-17 week-old WT and 
three mdx:utrn-/- mice were removed immediately after CO2 euthanasia, and fixed in 10% 
buffered formalin for 48 hours116. Then, they were cut axially into two equal sections and 
embedded in paraffin. Tissue processing and sectioning were done by the Pathology Core 
Facility at Robarts Research Institute (Western University, London, Ontario).  
 
2.4 Tissue Sectioning 
Tissue blocks were sliced in 5μm serial sections with a total of 40 sections for each block 
of cardiac tissue. To ensure that sections were representative of the whole cardiac tissue, 
serial sections were taken every 10 slices for histological analysis and fluorescent 
staining. The selected tissue sections (5 per heart) were deparaffinized and dehydrated 
with a series of xylene, 100%, 90% and 70% ethanol prior to staining.116 
 
2.5   Histological imaging 
   2.5.1 Image acquisition 
Hematoxylin and Eosin (H&E) and Masson’s Trichrome staining was performed by the 
Pathology Core Facility at Robarts to qualitatively assess tissue architecture and the level 
of fibrosis, respectively. Images were acquired on a Zeiss Axioscope microscope with 
Northern Eclipse software v7.0 (Empix Imaging Inc) under 10x, 20x and 40x objectives. 
Non-overlapping fields of view were taken to image the entire tissue for each section 
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with the 10x objective. As well, the entire tissue section was raster scanned at 10x to 
provide an unbiased view of the staining. To have more insight for each section, 6 fields 
of view were taken with the 20x and 40x objectives. 
 
2.6 Immunostaining 
For immunostaining, heat-mediated antigen retrieval was performed with 10 mM sodium 
citrate buffer in Phosphate Buffered Saline (PBS), pH =7.4, for 20 minutes prior to 
staining.116 Then, tissues were incubated with blocking buffer (10% Donkey serum 
(Sigma-Aldrich, D9663) + 1% bovine serum albumin (BSA) in PBS) for 1 hour at room 
temperature. Slides were then incubated with primary antibodies (antibodies are listed in 
Table 1 and described in Section 2.6.2) overnight at 4° C followed by incubation with 
secondary antibodies (listed in Table 1 and section 2.6.2) for 2 hours at room 
temperature. Finally, Cy5-ghrelin (1-19) (1:100) or Cy3-des-acyl-ghrelin (1-19) (1:100) 
were added to slides and incubated for 30 minutes. 
 
 2.6.1 Designing of fluorescent ghrelin analogs 
The fluorescent ghrelin analogs, Cy5-ghrelin (1-19) and Cy3-des-acyl-ghrelin (1-19), were 
used to detect GHSR and des-acyl-ghrelin binding, respectively, in the cardiac tissues. 
These probes were synthesized as described previously112. Structures are illustrated in 
Figure 2. 
 
 
A                                                         B 
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 Figure 2. Structure of ghrelin probes. A)  Structure of Cy5-ghrelin (1–19); 
(Dpr3(octanoyl), Lys19(Cy5) B) Structure of Cy3-des-acyl-ghrelin (1–19).  
 
    2.6.2 Antibodies 
A) F4-80: For immunofluorescent detection of macrophages, rat monoclonal anti-F4-80 
antibody (1:200, Abcam, ab16911) was used and visualized with Alexa Fluor-594 
conjugated donkey anti-rat IgG (1:500, Life Technologies, A21209). This antibody targets 
the F4-80 antigen (glycoprotein) that is expressed by murine macrophages. 
B) IL-6: To demonstrate the acute phase of the inflammatory response, mouse monoclonal 
anti-IL-6 (1:100, Abcam, ab9324) was used, followed by Alexa Fluor-594 conjugated 
donkey anti-mouse IgG (1:500, Life Technologies, A21203) for visualization. This 
antibody targets the IL-6 cytokine which is produced by cardiomyocytes, macrophages and 
adipose tissue. 
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C) Isolectin Conjugate: Isolectin GS-IB4 Alexa Fluor 488 Conjugate (1:100 Life 
Technologies, I21411) was used to stain the endothelial cells. This conjugate is composed 
of the Isolectin IB4 glycoprotein which is a part of the five tetrameric lectin family and 
targets -D-galactosyl residues on cell membranes. This conjugate labels the endothelial 
cells which are in the inner wall of the vasculature (microvasculature and 
macrovasculature), and also labels murine macrophages and laminin. 
D) CD36: Rabbit Polyclonal anti-CD36 antibody (1:250, Novus Biologicals, NB400-144) 
was used along with using Alexa Fluor-594 conjugated donkey anti-rabbit IgG (1:500, Life 
Technologies, A21206). This antibody marks the leukocyte differentiation antigen, CD36 
which is found in the tissues that are involved in lipid metabolism such as adipocytes, 
microvascular endothelial cells and cardiomyocytes. 
E) Nuclei were visualized with DAPI Prolong Diamond mountant (Thermo Fisher 
Scientific, P36962).  
 
To capture the background autofluorescent staining in the images, tissue sections were 
incubated only with the secondary antibodies (Alexa Fluor-594 conjugated donkey anti-
rabbit IgG, Fluor-594 conjugated donkey anti-mouse IgG, Alexa Fluor-594 conjugated 
donkey anti-rat IgG and Alexa Fluor-488 conjugated donkey-anti-mouse IgG). 
 
  
 2.6.3 Confocal Microscopy 
      2.6.3.1 Image acquisition  
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Sections were imaged on a confocal microscope (Nikon A1 R Canada) equipped with NIS 
Elements AIR 5.02.00 software using a 60x oil-immersion objective. The microscope was 
equipped with four lasers: DAPI (405nm), FITC (490nm-519nm), TRITC (561nm-594nm) 
and Cy5 (633-647nm), and they were switched on separately to reduce the cross-talk 
between the fluorochromes. Five sections were imaged per cardiac tissue and for each 
section, five regions of interest (ROIs) were captured. To visualize the microvasculature, 
the Nyquist option of image capturing was used to capture the field of interest and then 
image acquisition was done by higher pixel resolution (1024). To visualize the large 
vessels, five sections were imaged per cardiac tissue, and ten ROIs within the vessel 
structure were captured. To display the maximum contrast and brightness, images were 
deconvoluted using the 2D deconvolution algorithm on NIS Elements AIR 5.02.00.  
   2.6.3.2 Image analysis   
 The analysis was done using the ROI statistic option of the NIS Elements AIR 5.02.00 
software. 
A) Fluorescence intensity analysis was conducted on the 5 ROIs from each section and 
the intensity was normalized to the negative control (secondary antibody alone) as 
described above. The fluorescence intensity analysis was done for Cy5-ghrelin (1-
19), Cy3-des-acyl-ghrelin (1-19), F4-80, IL-6 and CD36. 
B) The extent of colocalization was determined by using the colocalization analysis in 
NIS Elements. This software generates a scatter plot of red and green 
(representative of CD36 and isolectin), green and purple (representative of Isolectin 
and GHSR), purple and red (representative of GHSR and IL-6, GHSR and F4-80) 
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were used to determine the levels of correlation between each pair of markers. 
Then, by using Coste’s algorithm the Pearson’s correlation coefficient (PCC) was 
computed.  
 
  2.6.3.3 Statistical Analyses 
Statistical analyses were conducted, and graphs were plotted using GraphPad Prism v.7.03 
(San Diego, California, United States). T-Test was used to compare the levels of GHSR 
between the DMD and age-matched WT using SPSS software v.24.0. A p value of <0.05 
was considered significant. To correlate the level of inflammation with GHSR, linear 
regression analysis was run on the F4-80 vs. GHSR data and also on IL-6 vs. GHSR data.  
 
 2.7 Cell Culture 
For mechanistic studies, mouse cardiac microvascular endothelial cells (MCEC) were 
purchased from Cedarlane (Burlington, Ontario, Canada). The MCECs were maintained in 
Dulbecco’s Modified Eagle Medium (DMEM) (Life Technologies, 11960-044) 
supplemented with 5% Newborn Calf Serum (NCBS) (Life Technologies, 16010142), 2 
mM L-glutamine (Life Technologies, 25030081) and 100 units/mL penicillin-streptomycin 
(Life Technologies, 15070063), at 37°C and 5% CO2. When MCECs reached 75-90% 
confluency they were dissociated from the plate with 0.25% trypsin/EDTA (Thermo Fisher 
Scientific,25200072) for 5 minutes at 37°C and 5% CO2 and then diluted in regular 
supplemented DMEM. The collected cells were seeded in 100-mm dishes for western 
blotting or on 60-mm tissue culture dishes containing glass coverslips for 
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immunocytochemistry studies. Treatment with 10 ng/mL, 250 ng/mL and 500 ng/mL of 
TNF-α (Abcam, ab9740) or vehicle control was performed in serum-free DMEM for 6, 16 
and 24 hours.117  
 
2.8 Immunocytochemistry and Immunofluorescence Microscopy 
   2.8.1 Immunostaining  
At the end of each treatment, cells were fixed with 2% paraformaldehyde (PFA) (Electron 
Microscopy Sciences, 15710-S) for 30 minutes at room temperature, permeabilized with 
0.25% Triton-X100 for 5 minutes and blocked with 1% bovine serum albumin (BSA) 
(Fisher Scientific, BP6711) in PBS for 1 hour at room temperature. The coverslips were 
incubated with the primary antibody, mouse anti-ICAM-1 (Intercellular Adhesion 
Molecule 1, 1:250, Abcam, ab171123), overnight at 4°C. Mouse anti-ICAM-1 targets the 
glycoprotein on the cell surface of the endothelial cells. Upon cytokine stimulation, the 
level of ICAM-1 increases in the endothelial cells.  
To visualize ICAM-1, cells were incubated with the secondary antibodies, Alexa Fluor-
488 conjugated donkey anti-mouse IgG (1:500), for 2 hours at room temperature. Then, 
cells were incubated with Cy5-ghrelin (1-19) (1:100) for 30 minutes to visualize GHSR. 
Coverslips were mounted using the Prolong Diamond mountants with DAPI (Thermo 
Fisher Scientific, P36962). As a negative control, cells were incubated with the secondary 
antibodies alone. 
   2.8.2 Confocal Microscopy  
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      2.8.2.1 Image acquisition  
Slides were imaged on a confocal microscope (Nikon A1 R Canada) equipped with NIS 
Elements AR 5.02.00 software using a 60x oil-immersion objective.  The microscope was 
equipped with four lasers including DAPI (405nm), FITC (490nm -519nm), TRITC 
(561nm-594nm) and Cy5 (633-647nm) and they were switched on separately to reduce the 
crosstalk between the fluorochromes.  Images were acquired from four slides per treatment 
at five regions of interest (ROIs) per slide. To display the maximum contrast and brightness 
in all images, the deconvolution algorithm on NIS Element AR 5.02.00 was applied in the 
same manner to all images.  
 
     2.8.2.2 Image analysis   
The analysis was done using the ROI statistic option of the NIS Element AR 5.02.00 
software as described in Section 2.6.3.3. The fluorescence intensity analyses for GHSR 
(Cy5-ghrelin (1-19)) and ICAM-1were conducted on the five ROIs from each slide and the 
intensities were normalized to their negative control. Colocalization analysis generated a 
scatter plot of green and red which represents the co-expression of ICAM-1 and GHSR. 
Coste’s algorithm computed the Pearson’s correlation coefficient (PCC) as stated above. 
2.8.2.3 Statistical Analyses 
Statistical analyses were conducted, and graphs were plotted using GraphPad Prism v.7.03 
(San Diego, California, United States). One-way ANOVA used to compare the levels of 
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GHSR and ICAM between the treated and untreated cells with TNF-α on the means of four 
technical replicates. A p value of <0.05 was considered significant. 
 
2.9 Cell lysates & Immunoblotting  
   2.9.1 Western blotting  
Cell lysates were prepared in radioimmunoprecipitation assay (RIPA) lysis buffer (Life 
Technologies, 89900) containing proteinase inhibitor mini-EDTA (Sigma Aldrich, 
11836153001). Protein content was quantified using a bicinchoninic acid (BCA) assay kit 
(BioVision, K813-2500). Thirty μg of total protein were loaded in each lane and separated 
on 4-12% NUPAGE gel (Invitrogen, NP0335). The resolved bands were transferred onto 
polyvinylidene difluoride (PVDF) membranes (Life Technologies, IB401001) using the 
iBlot® dry transfer system (Invitrogen). Membranes were blocked in 5% BSA in Tris-
buffered saline-Tween (TBST) for 1 hour at room temperature. Then, membranes were 
probed with primary antibodies including rabbit anti-GHSR (1:500, Santa Cruz 
Biotechnology, sc-374515) and anti-beta-actin (1:1000, Abcam, ab199799) overnight at 
4°C. Bands were visualized using secondary antibodies conjugated to horseradish 
peroxidase (HRP): goat anti-rabbit HRP (1:1000, Invitrogen, PI31460) and goat anti-
mouse HRP (1:1000, Abcam, ab6789). Bands were visualized with western ECL substrate 
(Thermo Fisher Scientific, 32106).  
2.9.2 Image acquisition and analysis 
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Membranes were imaged using a BioRad ChemiDoc Imaging System. Band intensities 
were determined by ImageJ FIJI version 1.46 (National Institute of Health, Maryland, 
United States) and normalized to the beta-actin band intensities. The values were 
statistically compared using one-way ANOVA. Densitometry units are displayed as mean 
± SEM and a p-value of <0.05 was considered significant. 
Table 1. Antibodies used for immunofluorescence microscopy. 
Antibodies Source Dilution Target Catalog 
Research 
Resource 
Identification 
number 
 Rat F4-80 Abcam 1:200 F4-80 
glycoprotein  
ab16911 
AB-443548 
Mouse IL-6 Abcam 1:100 IL-6 
Cytokine 
ab9324 
AB-307175 
Rabbit 
CD36   
Novus 
Biologicals 
1:250 CD36 
antigen 
NB400-144 
AB-10003498 
Mouse 
ICAM-1  
Abcam 1:250 ICAM-1 
glycoprotein 
ab171123 
 
Rabbit 
GHSR  
Santa Cruz 
Biotechnology 
1:500 GHSR sc-374515 
AB-10987651 
33 
 
 
 
Rabbit Beta-
actin  
Abcam 1:1000 Beta-actin Ab8227 
AB-2305186 
 Isolectin 
GS-IB4 
Alexa Fluor 
488 
Conjugate  
Life 
Technologies 
1:100 Endothelial 
cells 
I21411 
AB-2314662 
Alexa Fluor-
594 
conjugated 
donkey anti- 
Rat IgG 
Life 
Technologies 
1:500  A21209 
AB-2535795 
Alexa Fluor-
594 
conjugated 
donkey anti-
mouse IgG  
Life 
Technologies 
1:500  A21203 
AB-141633 
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Chapter 3 
3     Results 
3.1 Characterization of cardiac tissue pathology in the DMD heart 
 
I characterized the cardiac tissue pathology in wild-type and dmd (mdx:utrn-/-) cardiac 
tissues stained with hematoxylin and eosin (H&E) and Masson’s trichrome. For each slide, 
the entire tissue section of the myocardium in WT and DMD mice was screened to 
determine the full extent of degeneration and fibrosis. The left ventricular myocardium of 
DMD mice was mainly affected, so analysis focused on this region. We first compared the 
cellular organization between WT and DMD mice at 15-17 weeks of age (Figure 3). 
 In WT mice, cardiac muscle fibers were organized and had a cross-striation that provides 
the three-dimensional network connected by intercalated disks (Figure 3 panels A and B). 
Cardiomyocytes were either mononucleated or binucleated with a central nucleus in the 
extensive pinkish-red cytoplasm (Figure 3, panel C) In contrast, cardiac myofibers in 
DMD mice were shrunken, had lost their nuclei and striation, and stained palely with eosin 
(Figure 3 panel F). Vacuoles were also found within the cardiomyocyte sarcoplasm and 
could be a manifestation of myofiber necrosis and cardiomyopathy (Figure 3 panel E). 
Pyknotic nuclei and aggregation of lymphocytes indicate the necrosis and chronic 
inflammation within the myocardium of the DMD mice (Figure 3 panel E). Our findings 
illustrate that the pathology of cardio muscular dystrophy in DMD mice includes pyknosis 
(black arrow), lymphocytic infiltration (green arrow), vacuolization (red arrow). 
 
35 
 
 
 
 
 
Figure 3. Representative images of cardiac tissue architecture of the left ventricle in 
wild-type and DMD (mdx:utrn-/-) mice at 15-17 weeks of age(n=3). 
Cardiac tissue sections were stained with Hematoxylin and Eosin (H&E) and images were 
acquired at 10x, 20x and 40x magnification of the myocardium of the left ventricle in wild-
type (top row) and DMD (bottom row) mice. (B), Cardiac muscle fibers form the 
interconnecting three-dimensional network. (C), Cardiac muscle cells contain one or two 
nuclei which are centrally located with extensive eosinophilic cytoplasm; healthy cardiac 
fibers have regular cytoplasmic cross-striations. (E), Cardiac myofibers in DMD mice are 
loose without cross-striation. The red arrow indicates cardiomyocyte vacuolation that is a 
marker of cardiac degeneration. (F), The size of nuclei in the cardiomyocytes is variable. 
The black arrows show the shrunken myocyte and pyknosis in the myocardium. Yellow 
and green arrows indicate a fibroblast and lymphocyte aggregates, respectively. Boxes 
represent the magnified areas. 
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To determine the extents of both cardiac tissue degeneration and fibrosis simultaneously, 
we aligned the H & E and Masson’s trichrome staining in the same area of the cardiac 
tissue. To determine the level of fibrosis in the wild-type and DMD mice, Masson’s 
trichrome staining was performed to visualize the collagen content in the myocardium. The 
myocardium stained red while the collagen content was blue. We compared tissue 
morphology/architecture with the extent of fibrosis. In WT mice, cardiac myofibers in the 
lateral wall of the LV were uniformly red, organized and didn’t have any collagen staining 
(Figure 4, bottom row). In contrast, there was a significant amount of fibrosis in the lateral 
wall of the left ventricle in DMD mice (Figure 5, panel D). There were pyknotic nuclei 
and lymphocyte infiltration above the collagen fibers (Figure 5, panels C and F). 
Fibroblasts, which are the elongated (spindle-shaped) cells, were located adjacent to the 
collagen fibers (Figure 5, panel F).  
I also investigated the extent of fibrosis in the LV apex of DMD mice (Figure 6). At 10X 
magnification, the loss of organized architecture of myofibers was visualized, and there 
was a large extent of collagen and fat deposition in this area (Figure 6, panels A and D).  
At a higher magnification, pyknotic nuclei and aggregation of lymphocytes were seen 
(Figure 6, panels C and F), indicating cardiomyocyte necrosis and chronic inflammation, 
respectively. There are also large areas of adipose tissue and collagen deposition in the LV 
apex of the DMD myocardium that surround disorganized and degenerated myofibers 
(Figure 6, panel F).  
 
 
 
37 
 
 
 
 
Figure 4. Representative histology images of the left ventricle in wild-type cardiac 
tissue (n=3). Architecture of the heart in WT mice with 10x, 20x and 40x magnifications. 
(A, B, C) H&E staining of left ventricle myocardium in WT mice. Myocardial fibers are 
organized and have normal striation. The cardiomyocytes are either mononucleated or 
binucleated which are blue in color and centrally located. (D, E, F) Masson’s Trichrome 
staining of left ventricle myocardium in wild-type mice.  The cardiac muscle is bright red 
and there is no collagen content (blue staining) in the wild-type myocardium. (Boxes 
represent the magnified area) 
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Figure 5. Representative histology images of the left ventricle in DMD (mdx:utrn-/-) 
mice (n=3). (A, B, C) H&E staining at 10x, 20x and 40x magnification, respectively. 
Myocardial fibers are disorganized and have irregular striation. The cardiomyocytes’ 
nuclei are acentric and variable in size. The black arrow indicates an area of pyknotic 
nuclei, and the green arrow points to lymphocytes. (D, E, F) Masson’s trichrome staining; 
the panels align with the H&E staining above. (D), The diffuse pattern of collagen 
deposition in the DMD heart. (E), Cardiac myofibers show a loss of striation around an 
area of collagen deposition. (F), The size of nuclei in the cardiomyocytes is variable. The 
yellow arrows indicate fibroblasts adjacent to the area of collagen deposition. Boxes 
represent the magnified areas. Panels A and D are not completely aligned due to the blue 
artifacts in Masson’s Trichrome staining. 
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 Figure 6. Representative histology images of the left ventricular apex in DMD 
(mdx:utrn-/-) mice(n=3).  (A, B, C) H&E staining at 10x, 20x and 40x magnification, 
respectively. High magnification in panel C reveals the disruption in myocardial tissue 
organization, leukocyte infiltration, adipose tissue deposition (blue arrow) and neurons 
(yellow arrow). (D, E, F) Masson’s trichrome staining. These panels align with the H&E 
staining above. (E) There is diffuse fibrosis (blue) and cardiac tissue stains pale red. (F) 
The blue arrow indicates the adipose tissue in the myocardium and the adjacent myofibers 
are degenerated. (F) Yellow and blue arrows indicate neurons and adipose tissue, 
respectively. Boxes represent the magnified areas. 
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3.2 GHSR in cardiac tissue 
 
Our lab has previously shown that GHSR may be a biomarker of heart failure in humans 
114 and also a biomarker of diabetic cardiomyopathy in mice 113. The next set of experiments 
investigated if GHSR was present in the microvasculature of the heart, and how GHSR 
levels are altered with levels of inflammation during the progression of dilated 
cardiomyopathy in DMD mice.  
I stained the cardiac tissues with Cy5-ghrelin (1-19) along with AlexaFluor488-isolectin to 
evaluate the presence of GHSR in the microvasculature within the myocardium of WT and 
DMD mice. GHSR is present at very low levels in WT cardiomyocytes and is significantly 
elevated (p<0.0001) in DMD heart (Figure 7A and B). Microvessels in the myocardium 
of WT demonstrated an organized and cylindrical shape. The expression of GHSR was not 
seen in the microvessels since there was no colocalization between the isolectin and Cy5-
ghrelin (1-19) binding (Figure 7A).  In DMD mice, the cylindrical architecture of the 
microvessels in the left ventricle appeared to be disrupted, and there was also no 
colocalization between isolectin and Cy5-ghrelin (1-19) (Figure7A). Therefore, GHSR 
does not appear to be present in the cardiac microvasculature in either WT or DMD mice.  
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Figure 7. GHSR expression is elevated in DMD cardiac tissue. (A) Representative 
fluorescent images of the left ventricle in wild-type and DMD mice (mdx:utrn-/-). The 
cardiac tissues were stained with Cy5-ghrelin (1-19) and isolectin to show GHSR (purple) 
and microvessels (green), respectively. Nuclei were visualized with DAPI (blue). Cardiac 
microvasculature in the DMD heart looks aberrant and have an irregular shape; whereas, 
in wildtype, microvasculature has the normal circular shape. (B) GHSR fluorescence 
intensity is elevated in DMD mice (n=3, ****p<0.0001). Data are represented as mean 
fluorescence intensity ± SEM. Each bar represents fluorescence intensities from 5 ROIs 
from each of 5 sections per heart. 
 
 
3.3 Correlation between LVEF and GHSR 
Our previous results have shown a negative correlation between GHSR and Left 
Ventricular Ejection Fraction (LVEF) in patients who underwent cardiac transplantation.114 
As well, previous work from Dr. Hoffman’s group has shown the development of dilated 
cardiomyopathy in DMD mice at 15 weeks of age.59 In that study, they performed micro-
CT and echocardiography on wild-type and DMD mice to measure LVEF and showed that 
DMD mice had significantly decreased LVEF compared to WT mice. 
To more closely examine the relationship between GHSR and cardiac dysfunction, I 
performed linear regression analysis on the previously reported LVEF values and Cy5-
ghrelin (1-19) fluorescence intensities from the same WT and DMD mice in the present 
study. There is a strong inverse correlation between LVEF and myocardial GHSR 
expression (*p<0.05, r = -0.863). (Figure 8).  
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   Figure 8. Correlation between ejection fraction (%) and the level of GHSR in 
cardiac tissues in WT and DMD mice. There is a significant inverse correlation 
between the ejection fraction and Cy5-ghrelin (1-19) fluorescence intensity in the DMD 
cardiac tissue. Each data point represents values from one mouse. 
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3.4 Levels of GHSR correlate with levels of inflammatory markers  
To investigate the relationship between GHSR and inflammation, I stained the cardiac 
tissues with the macrophage marker F4-80 together with Cy5-ghrelin (1-19) and Alexa 
Fluor 488-isolectin. In WT myocardium, there is low expression of GHSR and no 
detectable expression of F4-80. AlexaFluor488-isolectin marked the cardiac microvessels 
in WT myocardium (Figure 9A, top panels). In contrast, there were markedly higher 
levels of F4-80 and Cy5-ghrelin (1-19) binding in the left ventricular tissue from DMD 
mice (Figure 9A, bottom panels), both of which were significantly different (p<0.0001) 
from WT (Figure 9B). Levels of F4-80 and Cy5-ghrelin (1-19) were strongly correlated 
(R2 = 0.97, p<0.004, Figure 9B). There were also higher levels of AlexaFluor488-isolectin 
fluorescence in the DMD myocardium (Figure 9A). Upon high-resolution imaging (Figure 
10), the fluorescent signals from AlexaFluor488-isolectin and F4-80 overlapped within 
discrete areas; therefore, AlexaFluor488-isolectin was also labeling macrophages in the 
DMD myocardium. As well, there was overlap with Cy5-ghrelin (1-19), suggesting that 
GHSR may be expressed in the cardiac macrophages in DMD myocardium (Figure 10). 
The identification of macrophages in the cardiac tissue from DMD mice at 15-17 weeks of 
age indicates chronic inflammation in the DMD myocardium.  
Pearson’s correlation coefficient of 0.926 between GHSR vs. F4-80 and of 0.784 between 
isolectin vs. F4-80 indicates colocalization between GHSR and macrophage marker and 
between the isolectin and the macrophage marker. 
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Figure 9. GHSR colocalizes with the macrophage marker F4-80. (A) Representative 
fluorescent images of the left ventricle in wild-type and DMD (mdx:utrn-/-) mice show 
Cy5-ghrelin(1-19), F4-80 and isolectin staining to visualize GHSR (purple), macrophages 
(red) and the vasculature (green), respectively. Nuclei are visualized with DAPI. (B) 
Quantification of fluorescence intensities for Cy5-ghrelin (1-19) (n=3, ****p<0.0001) and 
F4-80 (n=3, ****p<0.0001). Data are represented as mean fluorescent intensity ±SEM. 
Each bar represents fluorescence intensities from 5 ROIs from each of 5 sections per heart. 
Linear regression analysis indicates a strong correlation between GHSR and F4-80 
(****p<0.0004, R2 =0.9669). 
 
 
 
To examine further the relationship between GHSR and inflammation within the 
myocardium of the left ventricle in DMD mice, I assessed levels of the pro-inflammatory 
cytokine IL-6, along with Cy5-ghrelin (1-19) and isolectin (Figure 11A). Interestingly, IL-
6 expression was also seen in the lumen of the microvessels in the DMD mice, which might 
be an indicator of monocytes in the lumen, further indicating the extent of inflammation in 
the left ventricle of DMD mice (Figure 11A, arrows). Quantification of fluorescence 
intensities showed that IL-6 expression levels were significantly greater in DMD 
myocardium (****p<0.0001) and GHSR was also elevated in DMD (****p<0.0001) 
(Figure 11B). There was a strong correlation (***p<0.002, R2 =0.9286) between GHSR 
and IL-6. (Figure 11-B). 
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Figure 10. GHSR is expressed in cardiac macrophages. The ROI indicated in the top 
panel was subject to Nyquist analysis to increase the resolution. Cardiac tissues from DMD 
mice were stained with Cy5-ghrelin (1-19), F4-80 and isolectin to visualize the GHSR 
(purple), macrophages (red) and the vasculature (green), respectively. Nuclei were 
visualized with DAPI.  White color indicates the colocalization of the three signals (red, 
green and purple) which indicates the presence of GHSR in cardiac macrophages (arrows).  
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Figure 11. GHSR and the pro-inflammatory cytokine IL-6 are increased in cardiac 
tissue from DMD mice. (A) Representative confocal fluorescence images of the left 
ventricular myocardium in WT and DMD (mdx:utrn-/-) mice. Cardiac tissues were stained 
with Cy5-ghrelin (1-19), IL-6 and AlexaFluor488-isolectin to visualize GHSR, IL-6 
cytokine and the microvessels, respectively. Nuclei were visualized with DAPI. The arrows 
indicate the cardiac microvessels of WT mice (top row) and IL-6 staining within the 
microvessels in DMD myocardium (bottom row). (B) Quantification of fluorescence 
A 
B 
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intensities for GHSR (n=3, ****p<0.0001) and IL-6 (n=3, ****p<0.0001). Data are 
represented as mean fluorescent intensity ±SEM; each bar represents fluorescence 
intensities from 5 ROIs from each of 5 sections per heart.  Linear regression analysis 
indicates a strong positive correlation for the GHSR vs IL-6 in the cardiac tissues 
(***p<0.002, R2 =0.9286). 
 
 
3.5 GHSR and des-acyl-ghrelin binding in the large cardiac blood 
vessels. 
My results revealed that there is no GHSR in the cardiac microvasculature. Therefore, I 
asked if the GHSR exists in the large vessels in the heart. Since there is scarce information 
regarding the binding of des-acyl ghrelin in heart, I co-stained the cardiac tissues with Cy5-
ghrelin (1-19) and Cy3-des-acyl- ghrelin (1-19) to determine the binding sites in the large 
vessels of the vasculature. Interestingly, there was very little to no fluorescence signal in 
the vasculature (as determined by AlexaFluor488-isolectin staining) of WT mice. In 
contrast, there was detectable GHSR and des-acyl-ghrelin binding in the DMD cardiac 
macrovessels. (Figure 12A). Quantitative analysis of fluorescence intensities showed that 
the expression of GHSR (p<0.0001) and binding of Cy3-des-acyl-ghrelin (p<0.001) were 
both significantly higher within the cardiac microvasculature of DMD mice. (Figure 12B). 
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Figure 12. GHSR and Des-acyl-ghrelin in large vessels in cardiac tissues. (A) 
Representative fluorescence confocal microscopy images of large vessels in cardiac tissue 
of wild-type and DMD (mdx:utrn-/-) mice. The cardiac tissues were stained with Cy5-
ghrelin (1-19), Cy3-des-acyl ghrelin (1-19) and AlexaFluor488-isolectin to visualize 
GHSR, des-acyl-ghrelin binding and the large vessels, respectively. Nuclei were visualized 
with DAPI. Arrows indicate the large vessel in the cardiac tissues. (B) Quantification of 
fluorescence intensities for Cy5-ghrelin (1-19) (n=3, ****p<0.0001) and Cy3-des-acyl-
ghrelin (1-19) (n=3, ***p<0.001).  Each bar represents fluorescence intensities from 10 
ROIs within the vessel structure from each of 5 sections per heart. Data are represented as 
mean fluorescent intensity ± SEM. 
 
 
3.6 CD36 in Cardiac tissues 
The fatty acid transporter, CD36, is also present on microvascular endothelial cells. There 
is evidence that CD36 is upregulated in cardiac contractile dysfunction118. I assessed the 
presence of CD36 in myocardial tissue and vasculature in WT and DMD mice. CD36 was 
present in the microvascular endothelial cells in WT cardiac tissue as assessed by co-
localization with AlexaFluor488-isolectin (Figure 13A, top row). In DMD mice, the 
pattern of CD36 expression was more widely distributed throughout the tissue in structures 
that were both isolectin-positive and -negative (Figure 13A, bottom row). Quantitative 
analysis of fluorescence intensities showed that CD36 was present at significantly higher 
levels in DMD cardiac tissue (p<0.001) (Figure 13B). 
52 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
A 
W
T
D
M
D
 
0
2 0 0
4 0 0
6 0 0
8 0 0
1 0 0 0
C D 3 6
 M
e
a
n
 F
lu
ro
re
c
e
n
c
e
 I
n
te
n
s
it
y
(A
U
) ***p< 0.001 
Mean values+S.E.M (n=3)  
53 
 
 
 
Figure 13. CD36 levels in the left ventricular myocardium. (A) Representative 
fluorescent images of left ventricular myocardium in WT and DMD (mdx:utrn-/-) mice.  
The cardiac tissues were stained with Cy5-ghrelin (1-19), CD36 and AlexaFluor488-
isolectin to visualize GHSR, CD36 and the vasculature, respectively. Nuclei were 
visualized with DAPI. The CD36 expression is elevated in DMD in microvessels and in 
other structures which might indicate adipose tissue deposition in the myocardium of DMD 
mice. (B) Quantification of the fluorescence intensity for CD36 in the WT and DMD 
cardiac tissues. Each bar represents fluorescence intensities from 5 ROIs from each of 5 
sections per heart. Data are represented as mean fluorescent intensity ± SEM (n=3, 
***p<0.001) 
 
 
 
3.7 The effect of the pro-inflammatory cytokine TNF on GHSR 
expression in murine cardiac microvascular endothelial cells 
 
To further investigate the connection between GHSR and vascular inflammation, I used 
cardiac microvascular endothelial cells (MCEC)s that were cultured to confluency and 
treated with increasing concentrations of TNF-α. Cells were then assessed for GHSR by 
western blot analysis (Figure 14A).  Densitometric analysis of the GHSR-immunoreactive 
bands indicates that a dose of 500 ng/mL of TNF induces the highest level of GHSR in 
MCECs (Figure 14B). GHSR levels increased 4.5X upon treatment with 250 ng/ml TNF-
α (p<0.05), and over 15X upon treatment with 500 ng/ml TNF-α (p<0.001), indicating that 
GHSR is up-regulated in response to a pro-inflammatory stimulus.  
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Figure 14. GHSR increases upon treatment of MCECs with the pro-inflammatory 
cytokine TNF-α. (A) Cardiac Microvascular Endothelial Cells (MCEC)s were treated 
with 10, 250 or 500 ng of TNF- for 16 hours. Cell lysates were collected, and proteins 
were separated on a 4-12% NUPAGE gel. Membranes were immunoblotted for GHSR 
and beta-actin. (B) Densitometric analysis of GHSR normalized to -actin. Data are 
represented as mean ±SEM and one-way ANOVA was performed on the average of n=4 
separate experiments. *p < 0.05; ***p < 0.001. 
 
 
 
 
To visualize changes in GHSR levels and distribution within MCECs after cytokine 
stimulation, cells were cultured to confluency, treated with 10, 250 or 500 ng/mL of TNF-
α for 16 hours and stained with Cy5-ghrelin (1-19) and DAPI (Figure 15A). GHSR 
expression in MCECs is more cytoplasmic and the level of expression escalated in a dose-
dependent manner. 500 ng/mL treatment induced the highest level of GHSR in MCECs (p 
< 0.0001). (Figure 15B).  
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Figure 15. The level of GHSR increases with cytokine-induced inflammation in 
cardiac microvascular endothelial cells. (A)  Representative fluorescence images from 
MCECs that were treated with 10, 250 or 500 ng of TNF- for 16 hours, fixed and stained 
with Cy5-ghrelin (1-19) and DAPI to denote GHSR and nuclei. (B) Quantification of the 
fluorescence intensity of Cy5-ghrelin (1-19).  Each bar represents fluorescence intensities 
from 5 ROIs from each of 4 coverslips per treatment. Data represent the mean fluorescent 
intensity ±SEM and a one-way ANOVA was performed on the average of N=4 separate 
experiments. **p = 0.0058; ****p < 0.0001; ****p < 0.0001 
 
 
 
Upon cytokine stimulation, the level of ICAM increases in the endothelial cells. It is known 
that TNF-α increases expression of ICAM-1 through the NF-B pathway and ICAM-1 
promotes leukocyte adhesion and increases vascular permeability.119 120  My results 
indicated a dose-dependent increase of GHSR in MCECs treated with TNF-α. My question 
was whether the increase in GHSR occurred in parallel with an increase in ICAM-1. To 
answer this question, I treated MCECs with TNF-α and co-stained MCECs for ICAM-1 
(green) and with Cy5-ghrelin (1-19) (red). Both GHSR and ICAM-1 appeared as diffuse 
intracellular signals in MCECs (Figure 16A). Both GHSR and ICAM-1 expression 
increased in a dose-dependent manner (Figure 16B). However, there was no significant 
colocalization between GHSR and ICAM-1 in MCECs as assessed by Pearson correlation 
coefficient. (Figure 16C). 
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Figure 16. GHSR does not colocalize with the ICAM in MCECs treated with TNF- 
(A) Representative fluorescence images from MCECs that were treated with 10, 250 or 
500 ng/mL of TNF- for 16 hours, fixed and permeabilized, and stained with Cy5-
ghrelin(1-19), and for ICAM-1 and DAPI. (B) Quantification of the fluorescence 
intensities of Cy5-ghrelin (1-19) and ICAM-1.  Each bar represents fluorescence 
intensities from 5 ROIs from each of 4 coverslips per treatment. Data  represent the mean 
fluorescent intensity ±SEM and a one-way ANOVA was performed on the average of 
N=4 separate experiments (ICAM: **p = 0.0013; ****p < 0.002; ****p < 0.0001);    
(GHSR: **p = 0.0058; ****p < 0.0005; ****p < 0.0001) (C) Pearson’s correlation 
coefficient (PCC) indicate statistic colocalization between the ICAM-1 and Cy5-ghrelin 
(1-19). Data are represented as average PCC values ±SEM.*p< 0.01, N=4 separate 
experiments.  
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Chapter 4 
 
4 Discussion & Future Direction 
 
DMD is an X-linked disease that results from the loss of dystrophin and leads to the 
development of dilated cardiomyopathy resulting from inflammation, cardiomyocyte 
death, and fibrosis. Since 90% of DMD patients die due to heart failure, there is an 
emerging need to understand the cardiac manifestation of DMD. To date, there is no cure 
for DMD and most therapies for dilated cardiomyopathy have not been successful.  For a 
more beneficial therapy, we need to diagnose dilated cardiomyopathy at an early stage. 
Identification of tissue-specific biomarkers could open new doors for targeted therapies. In 
the work described in this thesis, I sought to characterize the cardiac pathology in a mouse 
model of DMD, mdx:utrn-/-, and to investigate whether GHSR could be a biomarker for 
DMD dilated cardiomyopathy.  
Briefly, the main objectives were: 1. To characterize GHSR and inflammatory markers in 
cardiac tissues in a mouse model of DMD; and 2. To characterize GHSR in vascular 
endothelial cells and determine its correlation with the level of inflammation. 
4.1 Characterization of cardiac tissue pathology in the mdx:utrn-/- mouse 
This is the first study that has evaluated the extent of cardiac degeneration in mdx:utrn-/- 
mice via histological techniques. Studies from our lab had previously measured functional 
changes during the development of dilated cardiomyopathy in vivo in the mdx:utrn-/-  
mouse model at 15-17 weeks of age with micro-CT and echocardiography. 59 The 
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histopathology of the skeletal muscle, but not the cardiac muscle, has been previously 
characterized by other research groups, including our group.121 122 123 124  In this study, I 
focused more on examining the left ventricle of DMD mice since in DCM, the left ventricle 
is mainly affected and also cardiac MRI has confirmed the particular involvement of the 
left ventricle in DMD patients. 21 125 
The gold standard histopathology staining, H&E, for mdx:utrn-/- mice detailed the extent 
of chronic inflammation in cardiac tissues at 15-17 weeks of age.  It showed the existence 
of lymphocyte aggregates in the lateral wall and apex of the left ventricle that is a hallmark 
of chronic inflammation. Pyknosis is a feature of myocardial necrosis which is sparse and 
more focal in mdx:utrn-/- mice, and it triggers macrophage migration to the site of tissue 
damage and cell death.76 126   
Cardiomyocyte vacuolation also presents in these mice which is another feature of 
myofiber necrosis and cardiomyopathy. Electron microscopy has shown that the 
vacuolization occurs due to damage in mitochondria or smooth endoplasmic reticulum 
(SER) which leads to sarcolemmal swelling and necrosis. The mechanism of the 
mitochondrial or SER damage is poorly understood but it may occur due to impairments 
in the ATP-dependent ion pump in the mitochondrial and SER membranes.127 128 
Cardiomyocyte vacuolization may also be the result of impaired blood flow associated with 
endothelial dysfunction and ischemia.129 
Fat deposition or lipomatosis in the DMD myocardium is a hallmark of chronic 
cardiomyopathy. Adipose tissue infiltration interferes with the intercalated disks that allow 
for synchronization of cardiomyocyte beating leading to arrhythmias and causing sudden 
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death. However, the mechanism by which adipose tissue forms and get stored in 
cardiomyopathy remains unknown. 45 130  
Fibrosis in the myocardium was detected in the left ventricle by Masson’s Trichrome 
staining. Fibroblasts form a fibrocollagenous scar tissue replacing cardiomyocytes, thereby 
impairing myocardial contraction. This myocardial fibrosis in the mdx:utrn-/-  mice was 
very diffuse, and there was more collagen deposition in the apex compared to the lateral 
wall of the left ventricle. This fibrotic pattern is very similar to what is seen in DMD 
patients and it is unique to dystrophinopathies. 30 131 
 
4.2 GHSR is elevated in myocardium of the mdx:utrn-/- mouse 
Having characterized the morphological changes of dilated cardiomyopathy in the 
mdx:utrn-/-mouse model, I investigated whether myocardial GHSR levels are altered in our 
model as assessed by the binding of our imaging probe, Cy5-ghrelin(1-19). With using this 
fluorescent peptide analog of ghrelin, our lab has previously shown that GHSR levels are 
altered before and after cardiac transplantation in humans, 114 and also in diabetic 
cardiomyopathy in mice .113  My results showed an elevation in GHSR in the myocardium 
of the mdx:utrn-/- mice at end-stage cardiomyopathy, which is in agreement with the 
elevated levels of GHSR that our lab has reported in end-stage human heart failure.114 
However, my results are in contrast with the mouse diabetic cardiomyopathy studies, where 
the level of GHSR is down-regulated using both fluorescence microscopy with Cy5-
ghrelin(1-19) and Western blot analysis.113 The reason for this discrepancy between the 
mice with diabetic cardiomyopathy and the mdx:utrn-/- mice could be possibly explained 
by the fact that they were in different stages of cardiac disease. Diabetic cardiomyopathy 
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mouse model showed very mild changes in heart function and no sign of inflammation or 
fibrosis. In contrast, the mdx:utrn-/- mice had late-stage cardiomyopathy, with a highly 
fibrotic and inflammatory pathology. Therefore, I suggest that GHSR is elevated in late-
stage cardiomyopathy, and down-regulated in early stage cardiomyopathy in mice. 
 
4.3 Correlation between left ventricular function, cardiac pathology and 
GHSR 
The functional features of dilated cardiomyopathy are an increase in left ventricular volume 
and decrease in EF.62 Previously, echocardiography and micro-CT had been performed on 
my experimental mice to show that LVEF was decreased.59 This decline in LVEF in DMD 
mice may also result in the severe pathology of the LV apex detailed in my study. It has 
been proposed that the apex of the heart may be the most susceptible region of the heart 
for thrombus formation due to lowered blood flow, which occurs in dilated 
cardiomyopathy. To this end, there are reports on apical thrombus in DCM- affected 
subjects which support this probable mechanism. 132 133 134 
My data showed a negative correlation between GHSR levels and LVEF. These results 
support our recent findings, which also demonstrated a negative correlation between the 
LVEF and GHSR levels in patients who underwent cardiac transplantation.114 I speculate 
that the elevated levels of GHSR in end-stage cardiomyopathy may be due to abnormal 
signaling of pro-survival pathways in response to cardiomyocyte damage, necrosis and 
apoptosis. These results suggest that GHSR may be an effective biomarker of LV function 
in DMD cardiomyopathy. 
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4.4   Chronic inflammation correlates with GHSR in DMD left ventricle 
This study is the first of its kind to correlate levels of GHSR with cardiac inflammation, as 
detected by macrophage infiltration and tissue cytokines.  A notable feature of chronic 
inflammation is the existence of lymphocytes and macrophages. Since H&E staining 
cannot differentiate between lymphocytes and macrophages, we used fluorescence 
immunostaining using F4-80 as a macrophage marker to detect the existence of 
macrophages in the DMD myocardium. In chronic inflammation, both M1 (pro-
inflammatory) and M2 (regeneration) macrophages are present.135 However, F4-80 cannot 
differentiate between M1 and M2 macrophages. To evaluate the macrophage phenotypic 
distribution, we need to use CD11c for M1 and CD206 as a marker of M2.136 Macrophages 
implements a range of important immunoregulatory and inflammatory functions by 
secreting chemokines and cytokines and also by degrading the extracellular matrix that 
surrounds cardiomyocytes. Damaged cardiomyocytes activate pro-inflammatory signaling 
pathways through NF-B which upregulates the production of pro-inflammatory cytokines 
such as TNF-α, IL-1 and IL-6. As well, the Toll-like receptor (TLR) family also plays an 
important role in tissue inflammation and cell death. Specifically, TLR4 was shown to be 
involved in DMD pathogenesis, as TLR4 genetic ablation in mdx mice resulted in dramatic 
blunting of macrophages, reduced fibrogenesis and increased capacity of skeletal muscle 
regeneration. 137. TLR4 could be  one of the key mediators in dilated cardiomyopathy since 
it initiates cytokine activation in damaged cardiomyocytes.138 Therefore, the dilated 
cardiomyopathy of DMD is highly inflammatory, and this process is mediated by both 
macrophages and cardiomyocytes. 
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My study has shown for the first time that GHSR is expressed in DMD murine 
macrophages in the myocardium. The expression of GHSR in macrophages may indicate 
a new role for ghrelin/GHSR in inflammation. A study showed that GHSR ablation in aged 
mice reduced the macrophage infiltrates and also promoted the macrophage phenotypical 
shift towards M2 (anti-inflammatory phase).139 As well,  GHSR is present and elevated in 
alveolar macrophages during sepsis-induced acute respiratory distress syndrome in rats, 140 
and ghrelin administration inhibited GHSR signaling through the Wnt/β-catenin pathway, 
reducing apoptosis and inflammation.  
My studies show an increase in the expression of the cytokine IL-6 in the cardiac tissue of 
DMD mice. These results are in agreement with the literature, which shows high levels of 
IL-6 in the serum and inflammatory infiltrates of DMD patients. There is evidence that IL-
6 is elevated in the diaphragm muscle of mdx mice.141 142 In the heart, IL-6 has dual roles 
in both cardioprotection and cardiac failure. In acute inflammation, IL-6 participates in 
neurogenesis and wound healing and maintains cardiac integrity. In contrast, in chronic 
inflammation, IL-6 activates constant signaling through the NF-kB pathway which leads 
to fibrosis.143 My results suggest that the elevated levels of IL-6 are due to chronic 
inflammation that will eventually lead to heart failure. There is a strong correlation between 
IL-6 and GHSR in DMD which indicate GHSR involvement in inflammation. This data 
may suggest that in inflammatory condition, GHSR is elevated to prevent apoptosis 
through PI3K and ERK1/2 pathway and also promote cell proliferation through PI3K and 
AKT pathway. 
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4.5 GHSR and des-acyl-ghrelin binding sites in the cardiac vasculature 
 My studies showed that there is no GHSR expression in cardiac microvasculature in both 
WT and DMD mice. I also showed that the arrangement of the microvasculature is 
aberrant in the DMD myocardium, which may cause left ventricle microinfarct which 
leads to necrosis. 77 144  However, the interpretation of these findings are limited, as 
AlexaFluor488-isolectin marked the microvasculature in WT mice, but was not specific 
to the vasculature in DMD mice, and also stained the murine macrophages.  
My results showed that there is binding of both Cy5-ghrelin (1-19) and Cy3-des-acyl 
ghrelin (1-19) in the cardiac macrovasculature, but not the microvasculature, in the DMD 
mouse. No binding of either probe was evident in the large vessels of WT mice. In contrast 
to Cy5-ghrelin (1-19), the binding of Cy3-des-acyl ghrelin (1-19) was observed only in the 
large blood vessels, and not in cardiomyocytes. Its colocalization with isolectin in the 
vessel wall, but not in cells within the lumen of the vessel, suggests that des-acyl ghrelin 
binding sites are on endothelial cells.112 The elevated ghrelin and des-acyl ghrelin binding 
in the DMD mouse might be an indicator of inflammation within large cardiac vessels. 
This is the first demonstration of both ghrelin and des-acyl-ghrelin binding in cardiac 
vasculature. I was able to detect binding sites for both ghrelin and des-acyl ghrelin in the 
same tissue due to our fluorescent ghrelin analogs which are very specific; Cy5-ghrelin (1-
19) binds specifically to GHSR in the mouse myocardium whereas Cy3-des-acyl-ghrelin 
(1-19) does not.112 Interestingly, it has been shown that des-acyl ghrelin inhibits cell death 
in endothelial cells through ERK1/2 signaling, but the receptor remains unknown.97  
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4.6 CD36 in Cardiac tissues 
CD36 is a fatty acid transporter. Normally, CD36 marks the microvascular endothelial cells 
in cardiac tissue, and under conditions of inflammation, CD36 is also expressed in 
cardiomyocytes, which could be evidence of cardiac dysfunction.145 In the DMD cardiac 
tissue, CD36 no longer appeared to be restricted to the microvasculature structure, which 
had lost the cylindrical structure and appeared aberrant.144 Our histopathology showed 
adipose tissue infiltration in DMD cardiac tissue; coupled with the observation of CD36 
immunoreactivity in isolectin-negative structures. Therefore, I suggest that the increase in 
CD36 may be due to this adipose tissue infiltration. It has been shown that CD36 increases 
in age-induced cardiomyopathy in mice as it is a major regulator of cardiomyocyte fatty 
acid uptake in cardiomyocytes.146 This finding suggests that the elevation in CD36 may 
promote myocardial lipotoxicity in mdx:utrn-/- mice. 
4.7 The effect of the pro-inflammatory TNF-α on GHSR expression in 
murine cardiac microvascular endothelial cells 
For preliminary mechanistic studies, I further explored the relationship between GHSR and 
inflammation in murine cardiac microvascular endothelial cells (MCECs). My experiments 
revealed that there is an expression of GHSR in MCECs and it is elevated upon exposure 
to the pro-inflammatory cytokine TNF- in a dose-dependent manner. These results are 
consistent with my animal studies that showed a positive correlation between GHSR and 
the pro-inflammatory cytokine IL-6 and the macrophage marker F4-80. However, there is 
a discrepancy, in that I found GHSR to be present in the large vessels of cardiac tissues 
under conditions of chronic inflammation, but not in the microvasculature. This apparent 
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discrepancy may be due to the fact that MCECs is an immortalized neonatal cell line, and 
the mouse tissues I used in this study, were from adult mice. Furthermore, to generate the 
MCECs, cardiac microvascular endothelial cells had been transfected by lentiviral vectors 
which carry the SV40 large T antigen and human telomerase. This cell line displays normal 
characteristics of endothelial cells but through genetic modification, some cellular 
functions may be altered and it’s a limitation for the cell studies. Therefore, GHSR 
expression in the neonatal microvascular endothelial cell line, but not in adult mouse 
cardiac microvascular endothelial cells, may indicate a role for ghrelin/GHSR in the 
maturation of these cells from the neonatal to adult stage.  
In endothelial cells, TNF-α increases expression of ICAM-1 through the NF-kB pathway 
and ICAM-1 promotes leukocyte adhesion and increases vascular permeability.119 120 
ICAM-1 expression was also increased in a dose-dependent manner but it didn’t colocalize 
strongly with GHSR in our model. The significance of these findings requires further 
investigations.  
 
4.8 Future Directions 
 
We demonstrated that GHSR could be a biomarker for inflammation in dilated 
cardiomyopathy in mdx:utrn-/- mice. To show the patterns in GHSR levels during the 
development of DCM in this mouse model, we need to conduct the experiments outlined 
in this thesis (correlation between inflammatory markers and GHSR) at earlier time points 
such as 4-5 and 8-10 weeks of age. 4-5 weeks of age is a very early stage of DMD with no 
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symptoms of cardiomyopathy; at 8-10 weeks of age, dilative cardiomyopathy is starting to 
develop in mdx:utrn-/- mice.59 
Future studies should introduce intravital microscopy along with the confocal microscopy 
and measure the blood flow in DMD vasculature and compare it with WT. This study will 
provide dynamic data on blood flow which could give more insight about DMD vasculature 
and how ghrelin-derived therapeutics could affect or correct the vascular structure.147 
Multiphoton laser scanning microscopy also could be used to study the DMD heart in 
depth. This microscope enables us to do the 3D histology and in vivo imaging of the heart 
with high-resolution and high-speed. With this microscope, we could visualize the beating 
heart in vivo with subcellular resolution and we could study the migration of leukocytes 
into the inflamed vasculature and cardiac tissue.148 
For mechanistic studies to establish the relation of inflammation and GHSR in endothelial 
cells, we need to silence GHSR through siRNA and determine how TNF-α induced 
inflammation affects inflammatory signaling pathways (E-selectin, AKT, PI3K and VE-
cadherin) in endothelial cells by western blot, IF and ELISA. 
To determine whether ghrelin has an anti-inflammatory effect on the endothelial cell, we 
could treat the MCECs with hexarelin (a GHSR agonist which is more stable than ghrelin) at 
different time points (30 min,70 min,6,24,48,72 hours) and determine the level of inflammation 
by western blot, IF and ELISA.  
Several studies demonstrated that ghrelin administration may improve skeletal muscle 
mass and function in mdx mice . 149 150 151 In future studies, we could administer ghrelin 
and des-acyl ghrelin to mdx:utrn-/- mice  and measure the pro-inflammatory cytokines in 
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plasma and also determine the level of GHSR and inflammatory markers in cardiac tissue 
and vasculature. This will elucidate whether ghrelin could be used as a therapeutic for 
DMD cardiomyopathy. 
 
4.9 Concluding remarks 
 
This study provides insight into the imaging GHSR in situ in DMD dilated 
cardiomyopathy. With the specific probe, Cy5-ghrelin (1-19), I showed a strong positive 
correlation between GHSR and inflammation markers which may suggest that GHSR could 
be a possible biomarker for chronic inflammation in dilated cardiomyopathy. The negative 
correlation between GHSR and LVEF proposed the GHSR as a heart function biomarker. 
Despite the advancements in imaging and biomarkers research for cardiomyopathy, 
distinguishing early pathogenesis and understanding disease mechanisms remain unsolved. 
Innovations in early recognition of cardiomyopathy can improve the survival and quality 
of life for patients and reduce the disease progression and hospital admission rate. These 
advancements also can open new doors for targeted therapies. Imaging GHSR in mdx:utrn-
/-
 mice represent a step towards the detection of early biomarkers for inflammation and 
dilated cardiomyopathy. 
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AUP Number: 2017-038 
PI Name: Hoffman, Lisa M 
AUP Title: Hoffman Breeding Protocol 
Approval Date: 05/30/2017 
Official Notice of Animal Use Subcommittee (AUS) Approval: Your new Animal 
Use Protocol (AUP) entitled "Hoffman Breeding Protocol" has been APPROVED by the 
Animal Use Subcommittee of the University Council on Animal Care. This approval, 
although valid for four years, and is subject to annual Protocol Renewal.2017-038::1 
1. This AUP number must be indicated when ordering animals for this project. 
2. Animals for other projects may not be ordered under this AUP number. 
3. Purchases of animals other than through this system must be cleared through the 
ACVS office. Health certificates will be required. 
The holder of this Animal Use Protocol is responsible to ensure that all associated 
safety components (biosafety, radiation safety, general laboratory safety) comply 
with institutional safety standards and have received all necessary approvals. Please 
consult directly with your institutional safety officers. 
Submitted by: Copeman, Laura  
on behalf of the Animal Use Subcommittee 
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